Screener
Amgen AMGN Business Segments — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Amgen’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000318154-26-000126
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Other revenues | 517 | 408 | 917 | 684 |
| Total revenues | 10,054 | 9,179 | 18,672 | 17,328 |
| Less: | ||||
| Manufacturing cost of sales(1)(2) | 2,139 | 2,484 | 4,319 | 5,012 |
| Profit share and royalties in cost of sales(1) | 672 | 527 | 1,236 | 967 |
| Research and development(1) | 1,868 | 1,744 | 3,587 | 3,230 |
| Sales and marketing(1) | 1,155 | 1,137 | 2,289 | 2,203 |
| General and administrative(1) | 590 | 554 | 1,058 | 1,175 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Amgen's business segments — cost of sales?
- Amgen (AMGN) reported business segments — cost of sales of $2.14B in Q2 2026.
- How has Amgen's business segments — cost of sales changed year-over-year?
- Amgen's business segments — cost of sales decreased by 13.9% year-over-year, from $2.48B to $2.14B.
- What does business segments — cost of sales mean?
- Includes the direct costs associated with the manufacturing, production, and distribution of the company's therapeutic products. This encompasses raw materials, labor, and overhead directly tied to the production of biologics. Monitoring this metric is essential for assessing the efficiency of the company's supply chain and manufacturing processes.
Ask your AI about Amgen's business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude